Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer

Xiaozhu Zhang, Alex Chang

Research output: Contribution to journalReview articlepeer-review

Abstract

Frequent overexpression of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), have been developed and approved by the US Food and Drug Administration for second-line and third-line treatment of advanced NSCLC. Clinical trials have shown considerable variability in the response rate between different patients with NSCLC, which led to the discovery of somatic EGFR-activating mutations. This brief review summarises the discovery and functional consequences of the mutations, their clinicopathological features and significant implications in the treatment and prognosis of NSCLC.

Original languageEnglish (US)
Pages (from-to)166-172
Number of pages7
JournalJournal of medical genetics
Volume44
Issue number3
DOIs
StatePublished - Mar 2007

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this